晚期黑色素瘤患者接受达拉非尼或达拉非尼联合曲美替尼治疗时循环肿瘤DNA的临床验证研究
该研究在COMBI-d和COMBI-MB两项试验中,用微滴数字PCR检测BRAFV600突变型ctDNA,评估其与靶向治疗预后的关联。结果显示基线ctDNA浓度升高与总生存更差相关,64拷贝/mL的切点可分层风险,第4周ctDNA转阴与生存延长相关。
要点
- 基线BRAFV600突变型ctDNA浓度升高与总生存更差独立相关。
- 64拷贝/mL的ctDNA切点可区分高风险与低风险患者。
- 第4周ctDNA转阴与无进展生存和总生存延长相关。
核心结论
- 治疗前和治疗中BRAFV600突变型ctDNA测量可作为靶向治疗预后的独立预测生物标志物。
研究设计与样本
- 临床验证研究,采用分析验证的微滴数字PCR检测两项临床试验患者的血浆样本。
- COMBI-d为双盲随机3期研究,比较达拉非尼联合曲美替尼与达拉非尼联合安慰剂。
- COMBI-MB为开放标签非随机2期研究,评估达拉非尼联合曲美替尼用于BRAFV600突变阳性转移性黑色素瘤伴脑转移患者。
- COMBI-d中345例(82%)有治疗前血浆样本,224例(53%)有第4周血浆样本;COMBI-MB队列A中38例(50%)有治疗前和治疗中样本。
主要发现
- COMBI-d中治疗前样本ctDNA检出率为320/345(93%),COMBI-MB队列A为34/38(89%)。
关键数值与推荐
- BRAFV600突变型ctDNA检测采用微滴数字PCR,基线浓度以64拷贝/mL血浆为切点分层高风险与低风险。
- 第4周ctDNA不可测定义为零转换状态,与生存延长相关。
临床怎么用
- 基线ctDNA浓度和早期清除情况可辅助风险分层,指导靶向治疗患者的监测与预后判断。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Melanoma lacks validated blood-based biomarkers for monitoring and predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising biomarker; however, various detection methods have been used, and, to date, no large studies have examined the association between serial changes in ctDNA and survival after BRAF, MEK, or BRAF plus MEK inhibitor therapy. We aimed to evaluate whether baseline ctDNA concentrations and kinetics could predict survival outcomes. METHODS: In this clinical validation study, we used analytically validated droplet digital PCR assays to measure BRAFV600-mutant ctDNA in pretreatment and on-treatment plasma samples from patients aged 18 years or older enrolled in two clinical trials. COMBI-d (NCT01584648) was a double-blind, randomised phase 3 study of dabrafenib plus trametinib versus dabrafenib plus placebo in previously untreated patients with BRAFV600 mutation-positive unresectable or metastatic melanoma. Patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. COMBI-MB (NCT02039947) was an open-label, non-randomised, phase 2 study evaluating dabrafenib plus trametinib in patients with BRAFV600 mutation-positive metastatic melanoma and brain metastases. Patients in cohort A of COMBI-MB had asymptomatic brain metastases, no previous local brain-directed therapy, and an ECOG performance status of 0 or 1. Biomarker analysis was a prespecified exploratory endpoint in both trials and performed in the intention-to-treat populations in COMBI-d and COMBI-MB. We investigated the association between mutant copy number (baseline or week 4 or zero conversion status) and efficacy endpoints (progression-free survival, overall survival, and best overall response). We used Cox models, Kaplan-Meier plots, and log-rank tests to explore the association of pretreatment ctDNA concentrations with progression-free survival and overall survival. The effect of additional prognostic variables such as lactate dehydrogenase was also investigated in addition to the mutant copy number. FINDINGS: In COMBI-d, pretreatment plasma samples were available from 345 (82%) of 423 patients and on-treatment (week 4) plasma samples were available from 224 (53%) of 423 patients. In cohort A of COMBI-MB, pretreatment and on-treatment samples were available from 38 (50%) of 76 patients with intracranial and extracranial metastatic melanoma. ctDNA was detected in pretreatment samples from 320 (93%) of 345 patients (COMBI-d) and 34 (89%) of 38 patients (COMBI-MB). When assessed as a continuous variable, elevated baseline BRAFV600 mutation-positive ctDNA concentration was associated with worse overall survival outcome (hazard ratio [HR] 1·13 [95% CI 1·09-1·18], p<0·0001 by univariate analysis), independent of treatment group and baseline lactate dehydrogenase concentrations (1·08 [1·03-1·13], p=0·0020), in COMBI-d. A ctDNA cutoff point of 64 copies per mL of plasma stratified patients enrolled in COMBI-d as high risk or low risk with respect to survival outcomes (HR 1·74 [95% CI 1·37-2·21], p<0·0001 for progression-free survival; 2·23 [1·73-2·87], p<0·0001 for overall survival) and was validated in the COMBI-MB cohort (3·20 [1·39-7·34], p=0·0047 for progression-free survival; 2·94 [1·18-7·32], p=0·016 for overall survival). In COMBI-d, undetectable ctDNA at week 4 was significantly associated with extended progression-free and overall survival, particularly in patients with elevated lactate dehydrogenase concentrations (HR 1·99 [95% CI 1·08-3·64], p=0·027 for progression-free survival; 2·38 [1·24-4·54], p=0·0089 for overall survival). INTERPRETATION: Pretreatment and on-treatment BRAFV600-mutant ctDNA measurements could serve as independent, predictive biomarkers of clinical outcome with targeted therapy. FUNDING: Novartis.
引用
- Syeda MM, Wiggins JM, Corless BC, et al. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncol. 2021. PMID: 33587894. doi:10.1016/S1470-2045(20)30726-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。